A phase III, randomized study of atrasentan in men with non-metastatic, hormone-refractory prostate cancer
Phase of Trial: Phase III
Latest Information Update: 08 Sep 2016
At a glance
- Drugs Atrasentan (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- 01 Nov 2008 Primary endpoint 'time to disease progression' has not been met.
- 01 Nov 2008 Results published in Cancer.
- 24 Feb 2007 Status change